FDA adds cardiovascular‑risk reduction claim to semaglutide U.S. label for adults with type 2 diabetes

The U.S. Food and Drug Administration has added a cardiovascular-risk reduction claim to semaglutide’s U.S. label for adults with type 2 diabetes, extending the drug’s profile beyond blood-sugar control and weight management. The change lands as drugmakers race to show GLP-1 medicines can do more than help patients lose weight. Novo Nordisk is also preparing new liver-disease data on semaglutide for EASL 2026, while Eli Lilly’s once-daily oral GLP-1, Foundayo, has already won FDA approval for obesity. At the same time, U.S. regulators are continuing to warn patients and prescribers about compounded GLP-1 products that have not gone through FDA review. ### What exactly changed on semaglutide’s U.S. label? The FDA-approved labeling now includes cardiovascular-risk reduction language for semaglutide in adults with type 2 diabetes, according to the source briefing and the updated U.S. label cited there. That matters because cardiovascular outcomes have become one of the most commercially important ways GLP-1 drugs differentiate themselves with doctors, payers and employers. (biospace.com) The approved semaglutide labels already show how broadly the molecule is being positioned across obesity, cardiovascular risk and liver disease. The current Wegovy label says semaglutide is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and it also includes an accelerated-approval indication for noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced fibrosis. (accessdata.fda.gov) ### Why does the cardiovascular claim matter beyond diabetes treatment? Novo Nordisk and its rivals are now competing on outcomes that affect reimbursement and long-term prescribing, not just pounds lost. A cardiovascular-risk reduction claim gives semaglutide a label statement tied to heart outcomes, an area payers and large health systems have watched closely as GLP-1 spending has risen. (accessdata.fda.gov) AJMC, cited in the source briefing, described the updated diabetes labeling as making oral semaglutide the first oral GLP-1 receptor agonist with an approved cardiovascular risk-reduction indication. That places the product in a category where convenience, adherence and clinical outcomes are all likely to be part of the sales pitch. ### Where does liver disease fit into the semaglutide story? (accessdata.fda.gov) Novo Nordisk said on May 19 that it would present new semaglutide data at EASL 2026 that build on its Phase 3 ESSENCE program in MASH. The company said earlier findings showed semaglutide 2.4 mg reduced liver inflammation and fibrosis in patients with MASH, a liver disease closely linked to obesity, type 2 diabetes and metabolic syndrome. (accessdata.fda.gov) Those presentations matter because they add another outcomes category to the same drug family. If cardiovascular and liver-disease data keep accumulating, semaglutide’s commercial case will rest increasingly on broader metabolic benefits rather than weight loss alone. That framing is an inference from the FDA label expansion and Novo Nordisk’s EASL agenda. (biospace.com) ### How much new pressure is coming from oral GLP-1 competition? The FDA approved Foundayo, Lilly’s oral GLP-1 drug orforglipron, on April 1 for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. The agency said the decision came 50 days after filing and 294 days before the application’s original PDUFA date, making it the first new molecular entity approved under the commissioner’s National Priority Voucher program and the fastest NME approval since 2002. (biospace.com) Foundayo is taken once daily by mouth and, according to the FDA, does not need to be taken on an empty stomach. That dosing profile gives Lilly a different commercial angle from oral semaglutide and adds pressure in a market that is quickly moving beyond a single-product story. ### Why are regulators still focused on compounded GLP-1s? (fda.gov) The FDA said unapproved compounded GLP-1 products do not undergo the agency’s review for safety, effectiveness or quality before marketing. The agency has cited concerns including improper shipping temperatures, product quality and the use of compounded versions that may be essentially copies of commercially available drugs. (fda.gov) FDA guidance issued on April 1 said compounders must meet statutory conditions, including limits on making products that are essentially copies of commercially available drugs. The agency also said it has established an import alert to help stop GLP-1 active ingredients with potential quality concerns from entering the U.S. supply chain. (fda.gov) ### What should readers watch next? EASL 2026 presentations by Novo Nordisk are the next scheduled catalyst for new semaglutide data, with liver-disease results expected to add detail to the company’s MASH program. In the United States, the next practical test will be how physicians, payers and patients respond as semaglutide’s cardiovascular positioning expands and Foundayo begins competing in the oral GLP-1 market under its April 1 FDA approval. (biospace.com) (fda.gov)